Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

VXA-CoV2-3.1

Phase 2Biologic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

SARS-Cov2Active, not recruiting

SARS-Cov2Phase 2

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

SARS-Cov2

NCT06672055

Clinical

Trials by Indication[1]

SARS-CoV21 trial

A Phase 2b, Double-Blind, Multi-Center, Randomized, Comparator-Controlled Trial to Determine the Relative Efficacy, Safety, and Immunogenicity of the Investigational Oral SARS-CoV-2 Vaccine Tablet Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Active, not recruiting·VVaxart·Phase 2·NCT06672055·5,485 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VXA-CoV2-3.1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VXA-CoV2-3.1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VXA-CoV2-3.1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vaxart company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: VVaxart

Related News